<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165564</url>
  </required_header>
  <id_info>
    <org_study_id>H-39556</org_study_id>
    <nct_id>NCT04165564</nct_id>
  </id_info>
  <brief_title>DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers</brief_title>
  <official_title>DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Radiology Imaging Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with
      indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis
      measured in minimally invasive and non-invasive biospecimens may be able to distinguish
      between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately,
      this study aims to validate molecular as well as clinical and imaging biomarkers of lung
      cancer in individuals with indeterminate lung nodules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a
      multidisciplinary and translational research program that previously initiated the DECAMP-1
      and DECAMP-2 studies for lung cancer early detection. Now, with the support of Johnson and
      Johnson, 3 Veterans Administration Hospitals (VAH), 3 Military Treatment Facilities (MTF) and
      12 academic hospitals as clinical study sites, several molecular biomarker laboratories,
      along with Biostatics, Bioinformatics, Pathology and Biorepository cores, we are expanding
      our work in lung cancer early detection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of lung cancer</measure>
    <time_frame>3 years</time_frame>
    <description>The number of new cases of lung cancer that developed divided by the population at risk.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Group 1 - Screening</arm_group_label>
    <description>Participants in this group will be 55-77 years old and currently smoke or were former smokers with 30 pack-years or more (and quit less than 15 years ago)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Incidental</arm_group_label>
    <description>Participants in this group will be &gt; 45 years old and currently smoke or were former smokers with 10 pack-years or more (and quit less than 15 years ago)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Institutional standard of care</intervention_name>
    <description>Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)</description>
    <arm_group_label>Group 1 - Screening</arm_group_label>
    <arm_group_label>Group 2 - Incidental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biosamples of airway and blood</intervention_name>
    <description>Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.</description>
    <arm_group_label>Group 1 - Screening</arm_group_label>
    <arm_group_label>Group 2 - Incidental</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Nasal brushing, Buccal scraping, Stool, Bronchial Biopsy, Bronchial brushing, Lung
      tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are identified for inclusion in the study based on the observation of a lung
        nodule on screening or incidentally found by routine chest CT scans, between 0.8-2.5 cm
        diameter or observation of a mixed density nodule in which the solid portion is 0.6-2.5 cm
        diameter. These patients are managed according to institutional standard of care. This may
        involve the use of LungRADS (screening setting) or Fleischner criteria (either combined
        2005, 2013 or 2017 guidelines)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiologic diagnosis of solid indeterminate pulmonary nodule (0.8 to 2.5 cm)
             identified in the past 3 months OR semi-solid (mixed density) nodule with solid
             component of at least 0.6 cm identified in the past 12 months; must be of appropriate
             size at enrollment.

          -  CT scan completed within 3 months prior to enrollment

          -  Able to tolerate all biospecimen collection as required by protocol

          -  Able to comply with standard of care follow up visits including clinical exams,
             diagnostic work-ups, and imaging for approximately three years from enrollment

          -  Able to complete the Patient Lung History questionnaire with study staff

        Arm 1 - Screening

          -  Age 55-77 years old

          -  Current and former smokers with 30 pack-years or more(and quit less than 15 years ago)

        Arm 2 - Incidental

          -  Age &gt; 45 years old

          -  Current and former smokers with 10 pack-years or more(and quit less than 15 years ago)

        Exclusion Criteria:

          -  History or previous diagnosis of primary lung cancer, metastatic lung cancer, or any
             other non-lung cancer within 5 years (not including non-melanoma skin cancer)

          -  Symptoms of lung cancer (unexplained weight loss 10 lbs or more in 3 months, recent
             hemoptysis)

          -  Diagnosis of pure ground glass opacities for the target lesion on chest CT within the
             last 12 months (i.e., mixed features on the target lesion and pure ground glass
             opacity on non-target lesions are acceptable as mentioned above)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab Billatos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denise Aberle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Washko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ehab Billatos, MD</last_name>
    <phone>617-358-7039</phone>
    <email>ebillato@bu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Dransfield, MD</last_name>
      <phone>205-934-5425</phone>
      <email>mdransfield@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kenneth Wei, MD</last_name>
      <phone>323-783-8191</phone>
      <email>Kenneth.K.Wei@kp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashley Prosper, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Greater LA Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steve Dubinett, MD</last_name>
      <phone>310-267-2725</phone>
      <email>sdubinett@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gina Lee, MD</last_name>
      <email>gina.lee@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>John Scott Parrish, MD</last_name>
      <phone>619-532-9067</phone>
      <email>John.Parrish@med.navy.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Yaron Gesthalter, MD</last_name>
      <email>yaron.gesthalter@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rolando Sanchez</last_name>
      <phone>319-353-8862</phone>
      <email>rolando-sanchez@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Browning, MD</last_name>
      <phone>601-395-0196</phone>
      <email>robert.f.browning2.civ@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronald Goldstein, MD</last_name>
      <phone>617-638-4860</phone>
      <email>ronald.goldstein@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>MeiLan Han, MD</last_name>
      <phone>734-615-9772</phone>
      <email>mrking@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wassim Labaki, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tobias Piekert, MD</last_name>
      <phone>507-284-4162</phone>
      <email>Peikert.Tobias@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>David Midthun, MD</last_name>
      <email>midthun.david@mayo.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Mazzone, MD</last_name>
      <phone>216-445-4812</phone>
      <email>mazzonp@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American College of Radiology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anil Vachani, MD</last_name>
      <phone>215-573-7931</phone>
      <email>avachani@mail.med.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Wilson, MD</last_name>
      <phone>412-687-4295</phone>
      <email>wilsondo@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Tennessee Valley Healthcare System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Massion, MD</last_name>
      <phone>615-322-3000</phone>
      <email>pierre.massion@Vanderbilt.Edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacob Jonas Carmichael, MD</last_name>
      <phone>757-953-5008</phone>
      <email>jacob.j.carmichael.mil@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ghulam Abbbas, MD</last_name>
      <phone>304-598-4779</phone>
      <email>ghulam.abbas@hsc.wvu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indeterminate pulmonary nodules</keyword>
  <keyword>Molecular biomarkers for lung cancer diagnosis</keyword>
  <keyword>Imaging for lung cancer diagnosis</keyword>
  <keyword>High risk smokers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

